bims-scepro Biomed News
on Stem cell proteostasis
Issue of 2026–11–08
twenty-two papers selected by
William Grey, University of York



  1. Blood. 2026 Nov 05. pii: blood.2026034629. [Epub ahead of print]
      Hematopoietic aging is marked by declining regenerative capacity and a shift from lymphoid to myeloid output. Previous studies have focused primarily on hematopoietic stem cells (HSCs), yet whether aging uniformly remodels the hematopoietic stem and progenitor cell (HSPC) compartment, or selectively affects distinct populations, remains largely unknown. To address this, we profile HSCs and multipotent progenitors MPP1-6 from young and aged mice across transcriptomic, epigenomic, metabolomic and lipidomic layers, together with single-cell division and in vivo serial transplantation assays. We identify young MPP6 (negative for CD150, CD34, CD48 and CD135) as an HSC-like, lymphoid-biased population with long-term reconstitution capacity, positioned within the top-tier of the differentiation hierarchy and marked by low global chromatin accessibility and metabolic activity. Upon aging, MPP6 preserved long-term lymphoid reconstitution, underwent limited transcriptional and regulatory remodeling, and did not accumulate polyunsaturated phospholipids or show mitochondrial oxidation. By contrast, most HSPCs, and particularly HSCs, underwent pronounced age-associated changes, including myeloid-biased expansion, metabolic rewiring, extensive distal regulatory alteration and accumulation of long-chain polyunsaturated phospholipids linked to increased oxidative stress. Pseudotime analysis further resolved the aged MPP6 compartment into two subsets, including a dormant, lymphoid-biased Dlk1-expressing population characterized by reduced mitochondrial activity, which was distinctly affected by inflammatory challenge in vivo. Together, these findings establish MPP6 as a comparatively resilient population within the aged HSPC compartment and suggest that it may represent a potential target for restoring hematopoietic balance.
    DOI:  https://doi.org/10.1182/blood.2026034629
  2. Cell Rep. 2026 Oct 30. pii: S2211-1247(26)01319-7. [Epub ahead of print]45(11): 118240
      Hematopoietic stem cells (HSCs) maintain their function through interactions with niche cells in the bone marrow. We previously demonstrated that protection of telomeres 1a (Pot1a), a shelterin component, maintains HSCs and neuron-glial antigen 2-expressing (NG2+) mesenchymal stem cells (MSCs) by suppressing DNA damage response (DDR) and reactive oxygen species (ROS) production. However, the role of Pot1a in leptin receptor-expressing (LepR+) MSCs, a primary HSC niche component, remains unclear. LepR-specific Pot1a knockout mice showed decreased LepR+ MSC numbers, increased DDR and ROS production, reduced HSC quiescence, and impaired long-term hematopoietic reconstitution. In contrast, cell-permeable Pot1a enhanced the hematopoietic-supporting function of LepR+ MSCs. Pot1a deficiency reduced pleiotrophin (Ptn) expression, whereas Pot1a overexpression increased its expression. These findings suggest that Pot1a preserves LepR+ MSC function by limiting stress-associated changes, maintaining MSC numbers, and regulating hematopoietic-supportive factor expression, including PTN.
    Keywords:  CP: stem cell research; DNA damage response; LepR(+) stromal cells; Pot1a; bone marrow niche; hematopoietic stem cells; mesenchymal stem cells; pleiotrophin; reactive oxygen species
    DOI:  https://doi.org/10.1016/j.celrep.2026.118240
  3. J Exp Med. 2027 Jan 04. pii: e20261384. [Epub ahead of print]224(1):
      Ex vivo expansion of hematopoietic stem cells (HSCs) is limited by culture-induced oxidative stress, yet the upstream transcriptional drivers remain poorly defined. Here, we show that the transcription factor Bcl11a is rapidly and persistently downregulated during HSC culture and that this decline drives functional deterioration. Bcl11a was both required and sufficient to maintain quiescence, clonogenic activity, and serially transplantable HSC function. Mechanistically, Bcl11a directly represses a Nox2 NADPH oxidase gene module, including Ncf1, encoding the p47phox organizer subunit; Ncf1 deletion reduced ROS and partially rescued the defects of Bcl11a-deficient HSCs. Rapamycin-but not the ROS scavenger N-acetylcysteine-restored Bcl11a expression, suppressed Ncf1 and ROS, and improved HSC function, identifying Bcl11a as a candidate effector linking mechanistic target of rapamycin complex 1 inhibition to redox control. This axis was conserved in human hematopoietic stem and progenitor cells, revealing a druggable transcriptional vulnerability of cultured HSCs and a framework for improving ex vivo-expanded grafts.
    DOI:  https://doi.org/10.1084/jem.20261384
  4. Exp Hematol. 2026 Nov 05. pii: S0301-472X(26)00596-5. [Epub ahead of print] 105963
      Ex vivo expansion of human hematopoietic stem cells (HSCs) has long been a major objective in regenerative medicine, with the potential to improve hematopoietic stem cell transplantation, enable more effective gene therapies, and broaden patient access to curative treatments. Despite decades of investigation, preserving long-term HSC self-renewal while achieving clinically meaningful expansion has proven challenging because HSC fate is tightly regulated by intrinsic molecular programs and the specialized bone marrow microenvironment. Over the past decade, however, substantial progress has transformed the field. The discovery of small molecules that modulate key regulatory pathways, advances in chemically defined culture systems, and a growing understanding of the cellular, biochemical, and biophysical cues provided by the bone marrow niche have led to significant improvements in ex vivo HSC maintenance and expansion. In parallel, the clinical translation of several expansion platforms has demonstrated the therapeutic potential of these approaches, particularly for umbilical cord blood transplantation and genome-edited HSC therapies. This Review discusses the biological principles underlying HSC expansion, summarizes current culture strategies, and highlights recent clinical advances. We also examine the remaining challenges associated with genomic stability, manufacturing scalability, and quality control, as well as emerging in vivo gene therapy approaches. Altogether, these advances are redefining HSC engineering and provide a foundation for the next generation of regenerative and gene-based therapies.
    DOI:  https://doi.org/10.1016/j.exphem.2026.105963
  5. Cell Stem Cell. 2026 Nov 05. pii: S1934-5909(26)00390-5. [Epub ahead of print]
      Programmable epigenome editing offers control of gene expression without altering DNA sequence, but its capacity to program human hematopoietic stem cells (HSCs) and their differentiated progeny remains incompletely characterized. Here, we establish that DNA methylation-based epigenome editors delivered transiently as RNA induce heritable gene silencing in primary human HSCs. Targeting the platelet integrin β3 (ITGB3) produced silencing that persisted through long-term HSC self-renewal and megakaryocytic differentiation, impaired aggregation of in vitro-derived platelets, and was partially reversed through targeted demethylation at this locus. Silencing remained stable in human HSCs 4 months after transplantation into mice. Targeting additional platelet-associated genes demonstrated broad applicability with this approach. Together, these findings establish DNA methylation-based epigenome editing as a platform for durable and reversible programming of human HSCs and demonstrate its application to modulating platelet function.
    Keywords:  DNA methylation; HSC engineering; epigenetics; epigenome editing; hematopoiesis; hematopoietic stem cell; platelet; thrombosis
    DOI:  https://doi.org/10.1016/j.stem.2026.10.009
  6. Sci Adv. 2026 Nov 06. 12(45): eaeg0571
      Acute myeloid leukemia (AML) is driven by genetic alterations and non-mutational mechanisms that disrupt normal hematopoiesis and support leukemic cell survival. While the mutational landscape of AML is well characterized, the non-genetic processes sustaining leukemic maintenance remain less understood. Using human AML cells and murine models, we identify BCL2-associated transcription factor 1 (BCLAF1) as a key regulator of leukemic progression through control of mRNA processing. BCLAF1 physically associates with core spliceosome components and regulates alternative splicing programs in leukemic cells. Mechanistically, BCLAF1 is required for productive splicing of activating transcription factor 4 (ATF4) mRNA, thereby sustaining ATF4 protein levels and downstream metabolic gene expression programs. Loss of BCLAF1 reduces ATF4 levels, leading to impaired de novo amino acid biosynthesis and increased sensitivity to venetoclax. Together, these findings uncover a previously unrecognized mechanism linking RNA splicing control to metabolic adaptation in AML, identifying BCLAF1 as a potential therapeutic vulnerability.
    DOI:  https://doi.org/10.1126/sciadv.aeg0571
  7. bioRxiv. 2026 Oct 28. pii: 2026.10.26.761955. [Epub ahead of print]
      Folic acid fortification for the prevention of neural tube defects has been a cornerstone of public health policy for nearly three decades, but its broader consequences for other developing organ systems, particularly the hematopoietic system, are poorly studied. Hematopoietic stem cell (HSC) emergence overlaps developmentally with neural tube closure, and folate-dependent one-carbon metabolism is critical for nucleotide synthesis, cellular methylation, and redox balance, positioning folate as a candidate regulator of HSC programming. Using dietary models of maternal folate deficiency or supplementation in mice, we demonstrate that maternal folate acts as a dose-dependent developmental tuner of hematopoiesis, programming adult offspring HSC function through divergent mitochondrial and chromatin states. Maternal folate deficiency impaired adult HSC self-renewal, associated with mitochondrial defects, disrupted cristae, elevated proteotoxic stress and a stress-adapted chromatin landscape. In contrast, maternal folate supplementation enhanced HSC self-renewal accompanied by improved mitochondrial quality control and CDC42-associated organelle remodeling, and established chromatin states permissive for stem cell maintenance. Fetal HSC metabolomics identified shifts in one-carbon intermediates, pyruvate and lipid pools, suggesting that divergent fetal metabolic states provide substrate-level inputs that drive persistent and opposing chromatin programs in offspring HSCs. Our findings establish maternal folate availability as an unappreciated regulator of lifelong hematopoietic output demonstrating that a single maternal micronutrient, folate, is sufficient to program adult HSC function and regenerative capacity through persistent metabolic and mitochondrial programming.
    DOI:  https://doi.org/10.64898/2026.10.26.761955
  8. bioRxiv. 2026 Oct 30. pii: 2026.10.28.758978. [Epub ahead of print]
      Gene therapies utilizing hematopoietic stem and progenitor cells (HSPCs) have curative potential across hematologic diseases, but manual manufacturing workflows are costly and difficult to scale, limiting patient access. Here, we demonstrated automation of an HSPC gene knock-in protocol on a high-throughput manufacturing platform designed for clinical-scale production. The platform executed all steps, from post-thaw HSPC inoculation through Cas9 electroporation, AAV6 transduction, and harvest, producing gene-edited HSPCs (geHSPCs) carrying an anti-HIV antibody transgene at the CCR5 locus with high purity, preserved differentiation potential, and editing efficiencies comparable to small-scale processing. Following transplantation into mice, geHSPCs engrafted and reconstituted multiple hematopoietic lineages, demonstrating that repopulation capacity was preserved. This work shows that clinical-scale doses of geHSPCs meeting release criteria can be produced on an automated, high-throughput platform, while preserving key product attributes and in vivo function, providing a path toward scalable and cost-effective manufacturing that could broaden access to HSPC gene therapies.
    GRAPHICAL ABSTRACT:
    DOI:  https://doi.org/10.64898/2026.10.28.758978
  9. bioRxiv. 2026 Oct 29. pii: 2026.10.28.761431. [Epub ahead of print]
      The myelodysplastic neoplasms (MDS) are initiated in hematopoietic stem cells (HSCs). Allogeneic transplantation is the only curative treatment, but relapse remains common. To detect rare MDS HSCs, we developed an ultra-low-input DNA sequencing assay and applied it to a multicenter post-transplant cohort. HSC mutation detection preceded relapse by a mean of 98 days and strongly predicted relapse (95.7% vs. 30.3%; hazard ratio, 8.8; P=1.5e-7). Mutations detected only in unfractionated marrow did not predict relapse. We developed methods to measure donor-host HSC chimerism, improving relapse prediction sensitivity. Single-cell protein, DNA, and RNA analyses with mitochondrial lineage tracing confirmed MDS cell enrichment within immunophenotypically- and transcriptionally-defined HSCs, identifying shared ribosomal gene downregulation and candidate mechanisms of venetoclax sensitivity. Venetoclax/azacytidine depleted detectable MDS HSCs in longitudinally evaluated patients. These findings establish that HSC mutation detection predicts post-transplant relapse, provide a rationale for preemptive intervention, and define shared biological features of transplant-resistant MDS HSCs.
    DOI:  https://doi.org/10.64898/2026.10.28.761431
  10. Stem Cell Reports. 2026 Nov 05. pii: S2213-6711(26)00352-8. [Epub ahead of print] 103141
      Gut microbiota dysbiosis caused by a high-fat diet disrupts hematopoietic stem cell (HSC) homeostasis; however, the underlying mechanisms remain unclear. Here, we identify gut microbial secondary bile acid deoxycholic acid (DCA) as a key mediator of HSC dysfunction in mice. Plasma DCA levels were elevated during aging, consistent with previously reported increases in high-fat diet-fed mice. Chronic DCA administration upregulated Spred1 in mouse HSCs, as also observed during aging, contributing to HSC loss. DCA treatment in Spred1-deficient mice triggered myeloproliferative neoplasm-like disease, highlighting Spred1's role in mediating a trade-off between HSC aging and tumor suppression. Unexpectedly, DCA-counteracting ursodeoxycholic acid also promoted age-associated expansion of myeloid-biased mouse HSCs. In contrast, a high-fiber diet lowered plasma DCA levels and mitigated aging-associated HSC decline. Our findings reveal that systemic gut microbial metabolites, particularly secondary bile acids, critically affect HSC fate, and suggest that dietary interventions targeting the gut microbiota can regulate hematopoietic homeostasis.
    Keywords:  aging; diet; hematopoietic stem cell; secondary bile acids; tumorigenesis
    DOI:  https://doi.org/10.1016/j.stemcr.2026.103141
  11. Cell Death Dis. 2026 Aug 09. pii: 943. [Epub ahead of print]17(1):
      A core complex with transcription factors (TFs) TAL1/TCF3/GATA2 and adaptors LMO2/LDB1 lies at the top of the hematopoietic transcriptional hierarchy. The mechanism(s) underlying the expression of these components remain elusive. Adaptor RACK1 interacts with multiple TFs and modulates their activation and/or stability. However, a role of RACK1 in the transcriptional control of hematopoietic stem cell (HSC) fates hasn't been disclosed. Here, we report that RACK1 is expressed across various hematopoietic cell types. Adulthood Rack1 deletion in type I interferon- (IFN-I)-responsive cells leads to rapid and profound hematopoietic failure and HSC loss. HSC exhaustion upon adulthood Rack1 deletion results from cell-intrinsic defects with massive apoptosis. Single-cell RNA sequencing indicates that adulthood Rack1 deletion in IFN-I-responsive cells leads to aberrant lineage-geneset-scores of transcriptional HSCs and the emergence of stressed HSCs. Furthermore, prenatal deletion of Rack1 in hematopoietic cells results in reduced and defective HSCs in the fetal liver. Mechanistically, RACK1 prevents HSC loss through maintaining the protein level of LDB1. The direct interaction between RACK1 and LDB1 suppressing its ubiquitination and subsequent degradation, thereby stabilizes LDB1. Therefore, RACK1 maintains adult and fetal mouse HSCs through, at least partially, directly binding to and stabilizing LDB1.
    DOI:  https://doi.org/10.1038/s41419-026-09177-z
  12. Cell Death Differ. 2026 Nov 03.
      Multiple myeloma (MM) is a refractory plasma cell neoplasm characterized by frequent development of drug resistance, leading to poor clinical outcomes. Activation of ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, has emerged as a promising cancer therapeutic strategy. In this study, we show that the circular RNA circ_0042819 exhibits high expression in both bone marrow and plasma samples from MM patients, with its overexpression strongly associated with disease progression and unfavorable prognosis. Mechanistically, circ_0042819 directly interacts with Up-frameshift protein 1 (UPF1) in MM cells, and the circ_0042819-UPF1 complex upregulates the expression of phospholipase A2 group VI (PLA2G6) via interacting with, and thus stabilizing, its mRNA. Furthermore, the circ_0042819-PLA2G6 axis suppresses ferroptosis through phospholipid remodeling in MM cells. Importantly, depletion of circ_0042819 or PLA2G6 enhances MM sensitivity to proteasome inhibitors (bortezomib and carfilzomib) by promoting ferroptosis both in vitro and in vivo. Collectively, our findings demonstrate that circ_0042819 is a potential non-invasive biomarker for the diagnosis and prognosis of MM, and that inhibition of the circ_0042819-PLA2G6 axis can mitigate the resistance of MM to proteasome inhibitors through ferroptosis sensitization, thus suggesting a novel therapeutic approach.
    DOI:  https://doi.org/10.1038/s41418-026-01847-x
  13. bioRxiv. 2026 Oct 28. pii: 2026.10.26.760729. [Epub ahead of print]
      Clonal hematopoiesis (CH) affects the aging population and is associated with increased risk of hematological malignancy, cardiovascular disease, and all-cause mortality. Therapeutic options for CH remain limited. Using hematopoietic stem and progenitor cell (HSPC) color barcoding and mosaic mutagenesis in zebrafish, we identified perturbed choline metabolism and increased phosphatidylcholine (PC) biosynthesis via choline kinase alpha (CHKA) in asxl1 -mutant HSPCs. Suppressing CHKA-dependent choline flux reduced ASXL1 -driven clonal expansion. This effect was conserved in a murine DNMT3A and human TET2 model. Mechanistically, CHKA-dependent choline flux controls phosphatidylcholine production that supports platelet activating factor (PAF) production. Exogenous PAF overcomes the suppressive effect of CHKA inhibition in ASXL1 and TET2 models. We isolated primary, human HSPCs from the peripheral blood of patients with endogenous ASXL1 mutations and demonstrated that perturbing PAF signaling reduces their competitive potential in an ex vivo clonal competition assay. This CHKA/PAF axis is conserved in TET2 -mutant HSPCs. Together, these findings identify a mutation agnostic metabolic dependency across the three most common CH genotypes and demonstrate that targeting the CHKA-dependent choline flux suppresses clonal expansion.
    DOI:  https://doi.org/10.64898/2026.10.26.760729
  14. Autophagy. 2026 Nov 03. 1-3
      Our recent study reveals how mitochondrial oxidative stress activates protective mitophagy in autoimmune thyroiditis. In thyroid epithelial cells, mitochondrial reactive oxygen species (mtROS) activate ATM serine/threonine kinase (ATM)-checkpoint kinase 2 (CHEK2) signaling. CHEK2 directly phosphorylates Tax1 binding protein 1 (TAX1BP1) at serine 722, enhancing its binding to lysine 63 (K63)-linked ubiquitin chains and promoting mitochondrial clearance. The nonphosphorylatable serine 722-to-alanine (S722A) mutant impairs mitophagy and increases cytosolic mitochondrial DNA (mtDNA) and stimulator of interferon genes (STING1) pathway activity. Deletion of either PTEN induced kinase 1 (Pink1) or parkin RBR E3 ubiquitin protein ligase (Prkn) aggravates thyroiditis in mice, whereas STING1 inhibition with C-176 reduces inflammation and thyroid autoantibody responses in both knockout models.
    Keywords:  Autoimmune thyroiditis; CHEK2; STING1; TAX1BP1; mitochondrial DNA; mitophagy
    DOI:  https://doi.org/10.1080/15548627.2026.2759221
  15. Cell Rep. 2026 Nov 06. pii: S2211-1247(26)01346-X. [Epub ahead of print]45(11): 118267
      Multiple myeloma is a plasma cell malignancy that develops within the bone marrow. The bone marrow metabolome is altered in myeloma, with implications for malignant cell growth. Here, the impact of elevated bone marrow levels of the tricarboxylic acid (TCA) cycle metabolite, succinate, was interrogated. Succinate was found to promote proliferation of several myeloma cell lines. This was linked to its uptake and oxidation in the TCA cycle, as indicated by increased ATP-coupled mitochondrial respiration and incorporation of succinate-derived carbons into downstream TCA cycle intermediates, which also occurs in primary myeloma cells. Succinate-driven proliferation was dependent upon mitochondrial oxidative phosphorylation and abrogated by ATP synthase inhibition. Furthermore, interrogation of large-scale transcriptomic data identified that elevated expression of a mitochondrial succinate transporter associates with accelerated disease progression in myeloma, indicating this mechanism may promote plasma cell growth in vivo and highlighting a target for therapeutic intervention.
    Keywords:  CP: cancer; CP: metabolism; anti-tumour immunity; cancer; cancer metabolism; immunometabolism; metabolism; metabolites; mitochondria; multiple myeloma; succinate
    DOI:  https://doi.org/10.1016/j.celrep.2026.118267
  16. Cell Death Differ. 2026 Oct 31.
      Adenosine deaminase 2 (ADA2) is a secreted enzyme recently shown to localize to lysosomes and bind DNA, yet its cellular function remains elusive. ADA2 is highly expressed by innate immune cells, particularly macrophages, which are implicated in the inflammatory pathogenesis of ADA2 deficiency (DADA2). Accordingly, we investigated its function in macrophages and identified ADA2 as a key regulator of mitochondrial quality control. Transcriptomic profiling of patient monocytes revealed upregulation of nuclear-encoded mitochondrial genes, alongside stress-response and apoptotic programs. Consistently, ADA2-deficient macrophages exhibited increased mitochondrial mass, hyperpolarization, elevated mitochondrial ROS and ATP production, structural abnormalities in cristae, and defective mitophagy. These defects promoted mitochondrial DNA leakage via VDAC, triggering cytosolic DNA sensing, cGAS-STING activation, and hyperactive JAK-STAT-mediated IFN-I responses. Restoration of ADA2 partially rescued mitochondrial integrity and dampened IFN hyperactivation in macrophages and zebrafish. Together, our findings identify ADA2 as a key regulator of mitochondrial quality control that prevents organelle dysfunction and limits inflammation driven by aberrant IFN signaling.
    DOI:  https://doi.org/10.1038/s41418-026-01893-5
  17. Cell Rep. 2026 Nov 02. pii: S2211-1247(26)01253-2. [Epub ahead of print]45(11): 118174
      Acute myeloid leukemia (AML) remains highly lethal, with treatment failure and relapse driven by dynamic cellular states and evolving interactions within the leukemic ecosystem. In this study, we built a comprehensive atlas of leukemia and its microenvironment (CALM) by integrating single-cell profiling from 73 AML samples and 9 healthy donors, bulk RNA sequencing (RNA-seq) from 87 newly diagnosed patients, and 4 paired bone marrow and peripheral blood single-cell data. All datasets were linked to clinical, cytogenetic, molecular, and treatment-response annotations. Immune analysis revealed diverse T cell distribution across disease status, where patients with persistent disease exhibited greater clonal expansion. Machine learning modeling on conventional T cells identified a T-cell signature pertinent to AML and outcomes, which were validated in two cohorts. CALM is a publicly accessible and interactive portal (calm.mdanderson.org) for exploring cellular compartments, cell-cell interactions, and longitudinal transcriptional and clonal dynamics to enable hypothesis generation, biomarker discovery, and target validation.
    Keywords:  CP: cancer; CP: immunology; T cell phenotype; clonotype; immune microenvironment; leukemia atlas; machine learning
    DOI:  https://doi.org/10.1016/j.celrep.2026.118174
  18. Photodiagnosis Photodyn Ther. 2026 Nov 04. pii: S1572-1000(26)00371-6. [Epub ahead of print] 105706
       BACKGROUND: Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) may show overlapping morphology on bone-marrow trephine sections, while definitive ancillary testing is not always immediately available. We evaluated whether microscopic hyperspectral imaging (HSI) combined with patient-level spectral-spatial deep learning could support differentiation of AML, ALL, and normal marrow.
    METHODS: This retrospective single-center study included 78 patients (26 AML, 26 ALL, and 26 normal marrow). H&E-stained bone-marrow trephine sections were imaged across 400-1000 nm. Patient-level nested stratified five-fold cross-validation was defined before region-of-interest (ROI) sampling to prevent information leakage. We developed HemaSpec-MIL, a new hierarchical spectral-spatial multiple-instance learning algorithm and a major methodological output of this study. The framework combines multi-scale spectral encoding, morphology encoding, bidirectional cross-attention, and gated multiple-instance aggregation to generate patient-level probabilities. The primary endpoint was pooled out-of-fold macro-AUC.
    RESULTS: HemaSpec-MIL achieved a pooled out-of-fold accuracy of 0.897, macro-F1 of 0.897, and macro-AUC of 0.957. One-vs-rest AUCs were 0.964 for AML, 0.945 for ALL, and 0.962 for normal marrow. Performance exceeded spectral-only, morphology-only, 3D-CNN, Vision Transformer, and spectral Transformer baselines. Ablation analysis supported complementary contributions from the spectral branch, morphology branch, cross-attention fusion, gated patient-level aggregation, and spectral augmentation.
    CONCLUSIONS: Microscopic HSI combined with the newly developed HemaSpec-MIL framework enabled accurate internal differentiation of AML, ALL, and normal marrow while preserving wavelength- and tissue-level interpretability. Independent multicenter validation and acquisition harmonization are required before clinical translation.
    Keywords:  acute lymphoblastic leukemia; acute myeloid leukemia; bone marrow pathology; deep learning; hyperspectral imaging; multiple-instance learning
    DOI:  https://doi.org/10.1016/j.pdpdt.2026.105706
  19. Cell. 2026 Nov 02. pii: S0092-8674(26)01139-6. [Epub ahead of print]
      When subject to damage or stress, cells develop responses in order to maintain tissue homeostasis. Two such responses are ferroptosis and cellular senescence, but how cells decide between these outcomes remains unclear. Here, we show that senescent cells increase import and membrane levels of multiple polyunsaturated fatty acids (PUFAs), but a specific intermediate PUFA, dihomo-gamma-linolenic acid (DGLA, 20:3ω-6), is reduced. Exogenous repletion of DGLA instead results in cell death by ferroptosis. Senescent cells manifest additional features associated with ferroptosis, including labile iron and expression of lipoxygenases as well as low-level membrane peroxidation. Oral DGLA supplementation lowers markers of senescence in aged mice and improves age-related functional outcomes. Finally, obese humans with lowered DGLA desaturation rates have lower markers of adipose tissue senescence. Together, our data implicate shifts in PUFA metabolism as a driver of decisions between senescence and ferroptosis.
    Keywords:  DGLA; PUFA; aging; desaturation; ferroptosis; lipid peroxidation; metabolism; obesity; senescence; senolytic
    DOI:  https://doi.org/10.1016/j.cell.2026.09.036
  20. Cell Death Differ. 2026 Nov 05.
      Recovery from tissue stress requires the elimination of damaged cells and the commensurate production of healthy cells. How these two processes are coordinated to ensure tissue recovery remains poorly understood. Here we show that the c-Jun N-terminal kinase (JNK) pathway orchestrates apoptosis and proliferation, two seemingly opposite cellular behaviours, in response to epithelial stress. We took advantage of new optogenetic tools to trigger a pulse of JNK signalling activity in a defined domain of Drosophila wing primordia and mapped the response in time and space. Within 3 h after induction, the cells within the activation domain arrest proliferation, while a subset undergo apoptosis. As JNK signalling returns to background level, apoptosis subsides and proliferation resumes to allow completion of development with high fidelity. Using a sensitive reporter, we find that while JNK triggers apoptosis, the level of JNK activity does not correlate with apoptosis on a cell-by-cell basis. We show that the cell cycle phase modulates the pro-apoptotic activity of JNK signalling: G2 arrest is protective, while, in G1, mild JNK signalling activity suffices to trigger apoptosis. Transcriptomic analysis identified the genes encoding Dally and Dally-like protein (Dlp) among the most upregulated by excess JNK signalling. We show that these glypicans contribute to tissue repair by enhancing surface retention of the ligands Wingless (a Wnt) and Dpp (a BMP). We suggest that the resulting local increase in morphogen signalling provides subsequent protection from the pro-apoptotic effect of JNK signalling, allowing surviving cells to re-enter the cell cycle and resume development. Accordingly, recovery from ribosomal protein deficiency or irradiation-induced stress is impaired upon reduction of Dlp activity. Our work shows how a single stress pathway can selectively trigger apoptosis while protecting cells that can contribute to tissue recovery during resumption of normal development.
    DOI:  https://doi.org/10.1038/s41418-026-01894-4